Soon after her diagnosis, Storm’s physician team ordered PreludeDx’s DCISionRT®, the only risk assessment test that predicts radiation therapy (RT) benefit in DCIS patients, to be run on her tumor ...

Delaying radiation therapy too long after surgery significantly increases the risk of recurrent tumors in women treated for very early, or what is referred to as "stage 0," breast cancer, according to ...

A newly released study is challenging the way doctors commonly treat patients with ductal carcinoma in situ (DCIS), known as stage zero breast cancer. DCIS cancer cells are confined inside a milk duct ...

LAGUNA HILLS, Calif., May 30, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx ®), a leader in precision diagnostics for early-stage breast cancer, today announced that it will share data ...

In this phase 3 trial, researchers aimed to study the efficacy of tumor bed boost and moderately hypofractionated whole breast irradiation in patients with non-low-risk DCIS.

Improving patient understanding of GEP test results (IMPARTER4): An RCT. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.

(CNN) — Danielle Fishel is sharing an update about her health. “I am officially done with radiation, which means I am officially done with what is considered active cancer treatment,” Fishel, 43, told ...

SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...

LAGUNA HILLS, Calif., Feb. 12, 2025 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced a partnership with Hannah Storm, ...